You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 23, 2024

CIRCANOL Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


When do Circanol patents expire, and when can generic versions of Circanol launch?

Circanol is a drug marketed by 3M and is included in two NDAs.

The generic ingredient in CIRCANOL is ergoloid mesylates. There are four drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the ergoloid mesylates profile page.

AI Research Assistant
Questions you can ask:
  • What is the 5 year forecast for CIRCANOL?
  • What are the global sales for CIRCANOL?
  • What is Average Wholesale Price for CIRCANOL?
Summary for CIRCANOL
US Patents:0
Applicants:1
NDAs:2
Raw Ingredient (Bulk) Api Vendors: 4
DailyMed Link:CIRCANOL at DailyMed
Drug patent expirations by year for CIRCANOL

US Patents and Regulatory Information for CIRCANOL

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
3m CIRCANOL ergoloid mesylates TABLET;SUBLINGUAL 084868-001 Approved Prior to Jan 1, 1982 DISCN No No ⤷  Subscribe ⤷  Subscribe ⤷  Subscribe
3m CIRCANOL ergoloid mesylates TABLET;SUBLINGUAL 085809-001 Approved Prior to Jan 1, 1982 DISCN No No ⤷  Subscribe ⤷  Subscribe ⤷  Subscribe
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

CIRCANOL Market Analysis and Financial Projection Experimental

Market Dynamics and Financial Trajectory for the Drug Channel: Insights and Trends

Introduction

The drug channel, a critical segment of the healthcare industry, is undergoing significant changes driven by consumer behavior, economic conditions, and advancements in pharmaceutical development. This article delves into the market dynamics and financial trajectory of the drug channel, highlighting key trends, opportunities, and challenges.

Current Market Trends

Sales Performance

In the fourth quarter of 2023, the drug channel experienced a decline in dollar sales by 5.7% compared to the previous year. This decline is partly attributed to consumers seeking value channels to save money, a trend that has continued from the COVID-19 pandemic era[1][4].

Price Inflation

Despite the decline in sales, average price inflation increased in the health and beauty departments, which account for 65% of total dollar sales in the drug channel. This inflation is a significant factor influencing consumer purchasing decisions[1].

Private Label Sales

Private label sales, which are often seen as a cost-effective alternative, declined in most departments. This decline suggests that consumers may be opting for national brands or seeking discounts elsewhere[1].

Consumer Needs and Opportunities

Health and Wellness Trends

Consumer needs in areas such as women’s health, healthy aging, sexual health, gut health, and sleep present substantial opportunities for growth in the drug channel. These niche areas are less affected by economic downturns and can drive sales through targeted product offerings[1].

Over-the-Counter Releases

The drug channel dominates sales for new over-the-counter (OTC) products in the initial months after launch. Capitalizing on these releases can be a strategic move to boost sales and market share[1].

Pharmaceutical Development and Innovation

Precision Medicines

The pharmaceutical industry is increasingly focusing on research and development (R&D) activities related to precision medicines. These medicines target smaller patient populations but offer high value per patient, leading to higher prices and potentially longer-lived profits[3].

Orphan Drugs

Orphan drugs, which treat rare conditions affecting small patient populations, have limited generic competition due to high development costs and small market sizes. This lack of competition allows firms to maintain higher prices even after patent expiration[3].

Economic Implications

Pricing Strategies

The shift towards precision medicines and orphan drugs changes optimal pricing policies. Firms must balance the high development costs with the potential for long-term profits from these niche markets[3].

Government Incentives

Government research and development incentives play a crucial role in supporting the development of drugs targeting small patient populations. These incentives help offset the high fixed costs associated with R&D[3].

Consumer Behavior and Financial Anxiety

Consolidation of Shopping Trips

Consumers are consolidating their shopping trips to value channels, reflecting financial anxiety and a cautious spending approach. This behavior negatively impacts traffic in the drug channel[4].

Impact of COVID-19

The COVID-19 pandemic led to significant growth in the drug channel due to increased demand for home health care kits and vaccination-related traffic. However, as vaccination efforts have slowed, the channel is experiencing a decline in sales[4].

Competitive Landscape

Generic Competition

The competitive landscape for generic drugs is evolving, particularly for complex biologic products. While the U.S. has a robust system of generic competition for small-molecule drugs, the market for biosimilars remains less competitive[3].

Market Entry Barriers

For new entrants, the fixed costs of entry and the likelihood of intense post-entry price competition make it challenging to earn profits in markets targeting small patient populations. This barrier limits generic competition in these niches[3].

Key Product Launches and Their Impact

Opill: Over-the-Counter Birth Control

The upcoming launch of Opill, an over-the-counter birth control pill, in early April 2024, is expected to be a significant event in the drug channel. As the first OTC birth control pill, it will likely dominate sales in the initial months after launch, providing a growth opportunity for the channel[1].

Challenges and Future Prospects

Data Collection and Analysis

Effective data collection and analysis are crucial for understanding drug utilization patterns and therapeutic effects. However, there are challenges in collecting detailed drug data due to concerns about response rates and the complexity of coding and classifying the data[2].

Regulatory Environment

The regulatory environment, including patent protection and government incentives, significantly influences the development and pricing of pharmaceutical products. Firms must navigate these regulations to optimize their R&D investments and pricing strategies[3].

Key Takeaways

  • The drug channel is experiencing a decline in sales due to economic factors and changes in consumer behavior.
  • Health and wellness trends offer opportunities for growth.
  • Over-the-counter releases and precision medicines are key areas for strategic focus.
  • Pricing strategies are evolving due to the shift towards targeting smaller patient populations.
  • Consumer financial anxiety and consolidation of shopping trips impact drug channel traffic.
  • Regulatory and competitive landscapes play critical roles in shaping the market.

FAQs

  1. What was the trend in drug channel sales in Q4 2023?

    • Drug channel dollar sales declined by 5.7% in Q4 2023[1].
  2. How has price inflation affected the drug channel?

    • Average price inflation increased in the health and beauty departments, accounting for 65% of total dollar sales[1].
  3. What opportunities exist for growth in the drug channel?

    • Consumer needs in women’s health, healthy aging, sexual health, gut health, and sleep present significant opportunities for growth[1].
  4. How do precision medicines impact the pharmaceutical market?

    • Precision medicines target smaller patient populations, leading to higher prices and potentially longer-lived profits due to limited generic competition[3].
  5. What is the significance of the Opill launch in the drug channel?

    • The Opill, an over-the-counter birth control pill, is expected to dominate sales in the initial months after its launch, providing a growth opportunity for the channel[1].

Cited Sources:

  1. Circana. U.S. Drug Channel Landscape Q4 2023.
  2. CDC. Vital and Health Statistics; Series 2, No. 90 (3/82).
  3. NBER. The Economics of Drug Development: Pricing and Innovation in a Changing Market.
  4. Circana. U.S. Drug Channel Landscape Report - Q1 2023.

More… ↓

⤷  Subscribe

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.